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Premature termination codonsWe sequenced the genomes of ten unrelated individuals and identiﬁed heterozygous stop codon-gain variants
in protein-coding genes: we then sequenced their transcriptomes and assessed the expression levels of the
stop codon-gain alleles. An ANOVA showed statistically signiﬁcant differences between their expression levels
(p=4×10−16). This difference was almost entirely accounted for by whether the stop codon-gain variant
had a second, non-protein-truncating function in or near an alternate transcript: stop codon-gains without
alternate functions were generally not found in the cDNA (p=3×10−5). Additionally, stop codon-gain
variants in two intronless genes were not expressed, an unexpected outcome given previous studies. In this
study, stop codon-gain variants were either well expressed in all individuals or were never expressed. Our
ﬁnding that stop codon-gain variants were generally expressed only when they had an alternate function
suggests that most naturally occurring stop codon-gain variants in protein-coding genes are either not
transcribed or have their transcripts destroyed.e Variation, Duke University
. Fax: +1 919 668 6787.
n).
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Premature termination codons (PTCs) are usually destroyed
through the process of nonsense-mediated decay (NMD). Without
this regulation, the incorrect transcripts could be translated into
proteins with potentially deleterious functions; conversely, in cases
where the resulting proteins have partial or nearly normal function, it
would be beneﬁcial if NMD did not occur. Indeed, NMD (and, less
commonly, its absence) has been shown to play a role in numerous
diseases, including β-thalassemia, Marfan syndrome and cystic
ﬁbrosis (reviewed in [1,2]). In mammals, NMD seems to rely on the
splicing and translation machinery; it can therefore only occur in
protein-coding transcripts that contain introns [3,4]. Furthermore,
NMD does not appear to function if the PTC is less than 50–55 bp
upstream of the ﬁnal splice junction of the gene (the “50 nt rule”);
thus PTCs within the ﬁnal exon do not tend to trigger NMD [5].
Additionally, there is some evidence that PTCs near the beginning of
the transcript also do not trigger NMD [6,7]; these ﬁndings have been
corroborated by genome sequencing studies that have observed that
naturally-occurring PTCs cluster in the 5′ and 3′ ends of genes [8]. The
NMD machinery is not entirely understood, but it seems that in
addition to disposing of potentially dangerous transcripts, it also plays
a major role in transcriptional regulation and the expression ofalternate splice forms (reviewed in [1,9]). Organisms with mutations
that disrupt the NMD machinery are often inviable [10–14].
Although there is a large body of knowledge about NMD, and it has
been found to exist in all eukaryotic species examined to date, it has
not previously been possible to investigate the expression of all
naturally-occurring stop codon-gain variants in a genome at once. The
recent advent of affordable Next-generation sequencing (NGS)
technologies has now made such studies possible. Here, we have
sequenced the genomes and transcriptomes of ten individuals; to
assess the expression of all naturally occurring PTCs, we have
identiﬁed high-quality heterozygous stop codon-gain variants in the
genomes and looked for allelic imbalances for these variants in the
transcriptomes.
2. Results
2.1. Identiﬁcation of variants
The genomes of ten individuals were sequenced to an average
coverage of 28.9×, with an average of 97% of the alignable bases of the
genome (i.e., excluding gaps in the reference) covered to at least 5×.
To obtain a reliable set of variants, we concentrated on high-quality
coding single nucleotide variants (SNVs) in protein-coding genes that
were observed in more than one of these 10 genomes, 65 control
genomes, 180 control exomes or dbSNP. Because we wanted to
identify allelic imbalances in the corresponding cDNA, we further
restricted to heterozygous variant calls: a total of 89,435 such calls
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some variants were found in multiple individuals. We then searched
for these variants in the PBMC transcriptome sequences from these
same ten individuals. To lessen the effect of a small sample size of
reads on allelic imbalances, all positions with less than 10× coverage
by RNA-Seq were discarded; the remaining average of 24 MB per
sample (covering approximately 34% of exonic bases) were se-
quenced to an average coverage of 67.0×. Thirty percent of the
locations corresponding to gDNA coding variant calls had at least 10×
coverage in the cDNA; 93% of these locations had a variant call that
matched the gDNA call (Table 1, Fig. 1).2.2. Imbalances at stop codon-gain variants
There were 85 heterozygous stop codon-gain variant calls,
corresponding to 42 variants, matching locations with at least 10×
coverage by RNA-Seq; this was a smaller portion of covered regions
than for other variant types, which is not unexpected as genes
heterozygous for PTC variants would conventionally be expected to be
expressed at approximately half the level of normal transcripts. In
contrast to the trends for stop codon-loss, nonsynonymous and
synonymous variants, where 80–95% of the variants were found by
RNA-Seq, only 60% of the stop codon-gains were found (Table 1). We
then looked at the percent of variant reads for each variant (number of
variant reads/(number of variant reads+number of reference
reads)). We note that the percent of variant reads for stop codon-
gain alleles in the RNA-Seq data was completely uncorrelatedwith the
corresponding values for the gDNA, indicating that any imbalances
seen were unlikely to be due to systematic biases. An examination of
the 21 stop codon-gain variants that were present in more than one of
the ten samples in this dataset and covered by at least 10 RNA-Seq
reads revealed that they were either not expressed in anyone (n=7)
or were expressed to some level in everyone (between 20 and 85% of
variant reads; n=14). Indeed, an ANOVA conﬁrmed the differences in
the percent of variant reads between the variants as signiﬁcant
(p=4×10−16); if restricted to the expressed stop codon-gain
variants, no differences between the variants were found (p=0.22).
Additionally, an ANOVA failed to ﬁnd a statistically signiﬁcant
difference in the percent of variant reads between the ten individuals
(p=0.97), even when restricting analysis to the expressed stop
codon-gain variants (p=0.29).
A full examination of the annotation for all 42 stop codon-gain
variants showed that 13 (52%) of the 25 stop codon-gain variants that
were expressed were also annotated as either nonsynonymous,
synonymous, or UTR variants in alternate transcripts. For example,
chr6:53,241,923CNA (GNT on the reverse strand) lies within two
transcripts: it changes a GGA codon to a TGA in ENST00000370918,
resulting in a PTC, and it changes a CTG codon to a CTT in
ENST00000304434, resulting in a synonymous change. These are
alternative transcripts for the same gene (ELOVL5); in
ENST00000370918, an exon is skipped that usually transitions the
phase from 1 to 0, resulting in a frameshift in the following exons that
does not produce a PTC unless this variant is introduced. Zero of the 17
stop codon-gain variants that were not expressed had alternateTable 1
Data for cDNA positions corresponding to the locations of gDNA exonic variants. All cDNA po
covered corresponding cDNA positions includes positions where no cDNA variant was calle
Stop codon-gain
High-quality gDNA variant calls 503
Corresponding covered cDNA positions
(% of gDNA calls)
85
(16.9%)
Corresponding covered cDNA positions with variant called
(% of covered corresponding positions)
51
(60.0%)
Mean % of variant reads for covered corresponding cDNA positions 28.0%annotations as nonsynonymous, synonymous, or UTR. Furthermore,
eight stop codon-gain variants that were expressed (67% of those
remaining) had received secondary annotations as intronic or upstream
or downstream of a gene; this was only true of three (18%) of the stop
codon-gain variants that were not expressed. A Fisher's exact test
conﬁrmed that expressed stop codon-gain variants were signiﬁcantly
more likely to have secondary annotations than were those that were
not expressed (p=3×10−5).
There were only four stop codon-gain variants that were
expressed but did not have alternate annotations in NCBI 36 Ensembl
release 50. Further examination of these variants found that three
were annotated in the updated GRCh 37 Ensembl release 57 as having
additional functions in alternate transcripts. The fourth, rs2272754 in
ZC3H3, lies only within one known transcript.
2.3. Positions and codon types of stop codon-gain variants
Thirty-one (74%) of the 42 stop codon-gain variants in this dataset
were found in codon position 1: 16 (52%) of these were expressed.
Although there was no statistically signiﬁcant difference between the
codon positions of the stop codon-gain alleles that were and were not
expressed, there was a trend for the stop codon-gains in positions 2 and
3 to be expressed. Of the four variants in position 2, all were expressed,
and of the seven variants in position 3, ﬁve (71%) were expressed.
Therewas no signiﬁcant difference between the type of stop codon
gained and whether or not it was expressed. Twenty-four percent of
the 42 stop codon-gain variants were TAA (70% expressed), 36% were
TAG (53% expressed), and 40% were TGA (59% expressed).
We also examined the relationship between the percent of variant
reads and the position of the variant within the coding sequence of the
gene andwithin the exon (Fig. 2). Therewasnot a signiﬁcant association
between either of thesemeasurements and either the percent of variant
reads orwhether the variant was expressed. Additionally, we compared
the percent of variant reads for stop codon-gains that were found in the
ﬁrst (n=7; 17%), the last (n=14; 33%), a middle (n=19; 45%), or the
only (n=2; 5%) exon of the gene (Fig. 2). Again, there was not a
statistically signiﬁcant difference between these groups, but therewas a
trend for stop codon-gains found in the last exon of the gene to have
higher expression (p=0.09). Finally, we compared the percent of
variant reads of stop codon-gains found less than 55 bp upstream of the
last splice junction (n=17; 40%) to those farther upstream (Fig. 2):
again there was no statistically signiﬁcant difference, but there was a
trend for higher expression of those less than 55 bp upstream of the last
splice junction (p=0.10).
2.4. Expression of genes containing stop codon-gain variants
For individuals with the same stop codon-gain variant, there was
no statistically signiﬁcant difference between the average reads per kb
of exon model per million mapped reads (RPKM) of genes with
expressed stop codon-gains and those with stop codon-gains that
were not expressed. There was a trend (p=0.07) for those genes with
stop codon-gains that were not expressed to have a higher RPKM, but
this was found to be driven by two outliers: stop codon-gains thatsitions were required to have a coverage of at least 10×. The mean % of variant reads for
d.
Stop codon-loss Non-synonymous Synonymous All coding variants
96 43,273 45,563 89,435
20 10,942 16,006 27,053
(20.8%) (25.3%) (35.1%) (30.2%)
16 9,977 15,158 25,202
(80.0%) (91.2%) (94.7%) (93.2%)
41.7% 46.2% 47.4% 46.9%
Fig. 1. Flowchart of methods.
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levels. These two genes were also found to have high RPKMs in
individuals who did not have the stop codon-gain variants.
For each gene, the average RPKM for individuals with a stop
codon-gain was also compared to the average RPKM for individuals
without stop codon-gains. A paired t-test of these average RPKMs did
not reveal a signiﬁcant difference between the groups.
2.5. Unique stop codon-gain variants
Although the above analyses focused onmore common variants, we
also examined unique stop codon-gain variants that were observed inFig. 2. Percent stop codon-gain variant reads. Shown by scaled position within a) the coding
scaled from 0 to 1 and are per individual, not averaged across individuals. The percent of vari
introns) and by d) whether the variant is within 55 bp of the ﬁnal splice junction (this catego
the means for each group.onlyoneof the ten samples andnoneof the245 controls ordbSNP. There
were 32 such variants in the gDNA; similar to what was observed for
more common variants, 5 (16%)were covered by at least 10 reads in the
cDNA. The stop codon-gain allele was not expressed for three of these
ﬁve variants; the other two had 42% and 71% of variant reads. One of the
expressed stop codon-gains was found to have alternate annotations as
both a synonymous variant and a 5′UTR variant, while the stop codon-
gains that were not expressed had no alternate annotations. Additional
analysis of the other expressed stop codon-gain variant showed that it
was included in a non-coding transcript in GRCh 37 Ensembl release 57.
The properties of the RPKM values, codon types, and positions of
the unique stop codon-gain variants were not signiﬁcantly differentsequence and b) the exon (which in some cases contains UTR). The values shown are
ant reads are also shown broken down by c) exon (“Only” indicates that the gene has no
ry necessarily includes the entire ﬁnal exon of each gene). Red crosses in c and d indicate
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(p=0.08) for unique stop codon-gains to occur closer to the 3′ end of
the exon than more common variants.
3. Discussion
In this study, we have examined the effect of PTCs on gene
expression by studying allelic imbalances at heterozygous stop codon-
gain variants in the RNA-Seq data of ten unrelated individuals. We
have found that the expression of alleles containing stop codon-gain
variants is generally blocked; the expression of such alleles largely
appears to occur only when the variant is also part of another
transcript, where it does not encode a stop codon-gain.
We feel that the most likely explanation for the imbalances seen
in the cDNA is NMD. It is worth noting, however, that there is
potential for the imbalances to be due to other factors, such as
unequal transcription. One possible explanation for the lack of
expression of some stop codon-gain variants would be that they lie
within an imprinted gene. However, none of the genes with stop
codon-gain variants studied here are found in the Catalogue of
Parent of Origin Effects or Geneimprint, although the lists provided
by these sources are of course not completely comprehensive
[15,16]. Another possible explanation could be RNA editing [17,18].
Additionally, NGS is not without errors, and a false positive variant
call in the gDNA could lead to what seems like an unexpressed
variant in the cDNA. Although we focused on high-quality gDNA
variant calls, we did not conﬁrm the variants studied here through
additional genotyping methods. It must also be noted that our RNA-
Seq data was based solely on RNA from PBMCs, so some of the
imbalances seen here may be tissue speciﬁc.
The results of this study demonstrate the importance of remem-
bering that variants can often havemultiple annotations. Twenty-four
(57%) of the 42 stop codon-gains examined here had alternate
annotations; of these 24, 21 were expressed. Although some of these
alternate annotations were not actually within a transcript (e.g.,
intronic or upstream), it seems possible that variants with multiple
annotations may lie within alternate transcripts that have not yet
been described or within transcripts that have been incorrectly
annotated as coding. For example, chr19: 63785276CNT is predicted to
be a stop codon-gain in ENST00000312426 and an intronic variant in
ENST00000237694 in NCBI 36 Ensembl release 50, but in GRCh 37
Ensembl release 57, it is annotated as a variant in the non-coding
transcript ENST00000493504. Conversely, of the 25 expressed stop
codon-gain variants, only 4 did not have alternate annotations.
Further investigation revealed that three of these four had alternate
annotations in the updated GRCh 37 Ensembl release 57, leaving only
one stop codon-gain variant that was both expressed and lacking a
secondary annotation in or near an alternate transcript. It is possible
that this variant has a secondary function in an alternate transcript
that has not yet been described; however, examination of the
expression patterns in this region did not suggest the existence of
another transcript. An alternative explanation is that this variant is
expressed due to its position proximal to the C terminus (position
0.93 in the coding sequence); previous studies have shown that such
PTCs are often expressed (reviewed in [9]). Indeed, 28% of the 25 stop
codon-gain variants that were expressed had scaled coding positions
of 0.9 or greater; this was only true of 6% of the 17 stop codon-gain
variants that were not expressed (Fig. 2). Although there was no
signiﬁcant association between the scaled positions within the coding
sequence of each PTC and either the average percent of variant reads
or whether a variant was called in the cDNA, there was a signiﬁcant
trend for stop codon-gain variants with secondary exonic annotations
to be closer to the C termini of genes (p=0.007).
We also examined whether variants in this dataset followed the
known “rules” of NMD: that for NMD to be triggered, the protein-
coding gene must contain introns and the variant must be greaterthan 55 coding bases from the last exon junction of the gene [3–5].
Only two genes with stop codon-gain variants, PABPC3 and
AL592309.24 (HS6ST1P1), were without introns (including the
UTRs). Contrary to expectation, the stop codon-gain alleles in both
of these intronless genes were not expressed. It should also be noted
that AL592309.24 is now annotated in GRCh 37 Ensembl release 57 as
a processed pseudogene, which are also not expected to undergo
NMD. We also found that 48% of the 25 stop codon-gains that were
expressed were found less than 55 bp upstream of the ﬁnal splice
junction; however, this was also true of 29% of those that were not
expressed (Fig. 2). While these results do not support the 50 nt rule,
there is prior evidence that this rule is not well followed in humans
[19].
We did not ﬁnd a signiﬁcant difference between the expression
levels of genes with expressed and unexpressed stop codon-gains.
Furthermore, we did not ﬁnd a signiﬁcant difference between the
expression levels of those individuals who had stop codon-gains and
those that did not. This is surprising given that genes not expressing
one allele would be expected to have lower transcript levels. While
past studies have shown that the overall expression of genes
decreases when they are undergoing NMD (for example, see [20]),
these studies have tended to focus on stop codon-gains that are
associated with diseases. A large-scale analysis of the effects of stop
codon-gains that are not associated with diseases on total expression
levels has not yet been performed. Although our study was performed
on a small number of samples and requires replication, our results
suggest that when seemingly harmless stop codon-gains are not
expressed, the loss of transcript may be compensated for with
increased expression of the alternate allele, perhaps via a feedback
mechanism. This observation implies that many heterozygous stop
codon-gain variants may not actually produce functional conse-
quences. If this is true, then it is a point worth considering in the
interpretation of sequencing studies, where stop codon-gain variants
are often categorized as being of the highest importance.
In this paper, we focused on SNVs, although PTCs can also occur as
a consequence of a small indel or larger structural variant.We chose to
only examine SNVs in this study because with the current technology,
this type of variant call is by far themost reliable [2]. In addition to the
fact that there are many false positive structural variant and indel
calls, these types of variants would also not be able to be assessed
directly in the RNA-Seq data: it is not possible to use such data to call
structural variants by the read depth method, and the calling of indels
is difﬁcult because of the need to align reads that cross splice
junctions. As another means of assuring that we focused on high-
quality variants, in the main analyses of this paper we only examined
variants that were found in more than one individual (including 245
controls and dbSNP). However, we also examined unique stop codon-
gain variants separately and found that their properties were not
noticeably different from those of the more common stop codon-gain
variants.
Previous studies have demonstrated inter-individual differences in
NMD efﬁciency and differences in the propensity of different PTCs to
succumb to NMD (reviewed in [9]). However, in this study we have
found that naturally occurring stop codon-gain variants are generally
not expressed unless they have secondary annotations in or near
other transcripts. Though our sample size is admittedly small, we do
not ﬁnd inter-individual or inter-variant differences in PTC
expression.
While there have been numerous studies of NMD, ours is the ﬁrst
study to take an unbiased look at PTCs across a fully sequenced
genome and examine their level of expression. Such an analysis was
not possible until very recently; before Next Generation sequencing
technologies arose, identifying all of the stop codon-gain variants that
were present in multiple genomes would not have been feasible. The
results of our study suggest that NMD, which has long been known to
work efﬁciently in the speciﬁc genes in which it has been studied,
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genome manner.4. Methods
4.1. Samples, preparation and sequencing
The samples used in this study represent a partial overlap with
those presented in previous works; six of the ten genomes discussed
have already been published [2], as has one of the transcriptomes [21].
DNA was extracted from peripheral blood mononuclear cells
(PBMCs) using the QIAGEN Autopure LS. RNA was extracted from
viable PBMCs using the Qiagen RNeasy kit. The DNA was prepared for
sequencing according to Illumina's gDNA sample prep kit protocol:
brieﬂy, the DNA is randomly fragmented by nebulization, then
undergoes end repair, a single A base is added, adaptor ligation occurs,
a gel is run to isolate appropriately-sized fragments, and ﬁnally
polymerase chain reaction (PCR) ampliﬁcation is performed. One
microgram of total RNA was prepared for each sample according to
the Illumina RNA-seq protocol: brieﬂy, globin reduction, polyA
enrichment, chemical fragmentation of the polyA RNA, cDNA synthesis,
and size selection of the cDNAproducts. Next, the size-selected libraries
were used for cluster generation on the ﬂow cell. All prepared ﬂow cells
were run on the Genome Analyzer II using the paired-end module.4.2. Alignment
gDNA was aligned to the reference genome (NCBI Build 36) using
the BWA software [22]. cDNA was aligned to the reference genome
using TopHat [23]. The -GFF option utilized a transcript library
downloaded from Ensembl release 50 to specify known protein-
coding transcripts and splice junctions (although novel junctions
were permitted), and the library was screened to remove contigs and
mitochondrial DNA. The mate inner distance (option –r) was
calculated using the fragment and read sizes of each sample. A
minimum anchor length (option –a) of four was used. To assist in
alignment to small exons, the 100 bp reads were broken down into
four segments of default length 25 bp that were then joined back
together after being individually aligned. Two mismatches were
permitted per 25 bp segment, and no mismatches were permitted in
the 4 bp anchor region on either side of a splice junction. Introns were
permitted to range in size from 10 bp to 500 kb.4.3. Transcript expression quantitation and variant identiﬁcation
RPKM values were calculated using Partek software and visualized
using custom tracks in the UCSC genome browser [24].
SAMtools was used to call SNVs in the gDNA and cDNA alignments.
Indels were not considered because they are less reliable [2] and the
TopHat [23] alignment did not support the gaps required for indel
calls. Prior to variant calling, SAMtools ﬁrst removed potential PCR
duplicates via the rmdup (paired reads) command [25]. It was also
used for SNV identiﬁcation, using the pileup command with the –c
option and default settings. The SNVs were then ﬁltered using
SAMtools' variation ﬁlter with the default settings but changing the
ﬁlter for the maximum allowed coverage per variant to 254 for gDNA
and 1 million for cDNA. SNVs lying outside exons as deﬁned by the
transcript library were removed.
Structural variants (SVs) were identiﬁed from the whole-genome
sequences using ERDS v.1.02 (http://www.duke.edu/~mz34/erds.
htm) with a sliding window size of 2 kb. None of the expressed stop
codon-gain variant calls in this paper were found within regions
predicted to be duplicated by this method.4.4. Annotation, QC and visualization
The Sequence Variant Analyzer (SVA) software (svaproject.org) [26]
was used to annotate the function (synonymous, nonsynonymous, stop
codon-gain or stop codon-loss) of each variant according to NCBI 36
Ensembl release 50. After annotation, SVAwas used to exclude all gDNA
SNVs that did not meet minimumQC requirements: a SNP quality score
of at least 20, a consensus score of at least 20, and at least 3 reads
supporting the variant. cDNA SNVs called by SAMtools were not further
screened by SVA. Analysis was restricted to those variants lying within
the 21,021 genes that were annotated as protein-coding. Furthermore,
we excluded all variants that exhibited allelic imbalances in the gDNA,
requiring that the percent of variant reads (number of variant
reads/(number of variant reads+number of reference reads)) was
between 40 and 60%. Additionally, we restricted our analysis to the
autosomes as all subjects were male. For the main analysis, we focused
only on variants that were present in more than one individual,
considering the other nine samples as well as dbSNP, 65 control
genomes and 180 control exomes that had been sequenced as part of
other projects. This was done to increase the likelihood that the SNVs
were real. SVA was used to visualize the variants and to determine the
position within the coding sequence of stop codon-gain variants; all
positions were scaled so that 0 represented the ﬁrst base and 1
represented the last.4.5. Identiﬁcation of allelic imbalances and statistical analysis
For the RNA-Seq data, analysis was restricted to locations with at
least 10× coverage. The RNA-Seq percent of variant reads was
determined for each variant, and locations that had no variant called
were assumed to have 0% of variant reads. The number of gDNA-
matching variants called by RNA-Seq and the average percent of
variant reads can be found in Table 1.
All statistical analyses were performed using STATAwith a p-value
cutoff of 0.05 [27]. Comparisons between two continuous variables
were made using a linear regression, comparisons between a
continuous variable and a discrete variable were made using
ANOVA, and comparisons between two discrete variables were
made using Fisher's exact test. A paired t-test was used to compare
each gene's average expression in individuals with a stop codon-gain
to those without.Acknowledgments
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